Bristol Myers Squibb (CELG-RI) Gross Margin (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Gross Margin of 71.28% for Q2 2026, down 124.0% year-over-year from 297.0% in Q2 2025, and up 1.5% quarter-over-quarter from 70.22% in Q1 2026.
Bristol Myers Squibb (CELG-RI) Gross Margin (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Gross Margin for 18 consecutive years, with 71.28% the latest figure, recorded in Q2 2026.
- In Q2 2026, Gross Margin fell 124.0% year-over-year to 71.28%; the TTM figure through Jun 2026 stood at 70.16% (down 13.0% YoY), while the FY2025 annual figure was 71.08%, changed 0.0% from the prior year.
- Gross Margin rose to 71.28% in Q2 2026 per CELG-RI's latest filing, from 70.22% in the prior quarter.
- Across five years, Gross Margin topped out at 79.02% in Q3 2022 and bottomed at 61.01% in Q4 2024.
- Historically, Gross Margin has averaged 73.77% across 5 years, with a median of 74.76% in 2023.
- Annual changes were most pronounced in 2024 — Gross Margin plunged 1507 bps — and 2025, when it surged 622 bps.
- Bristol Myers Squibb's Gross Margin stood at 77.27% in 2022, then dropped by 2 bps to 76.08% in 2023, then decreased by 20 bps to 61.01% in 2024, then climbed by 10 bps to 67.23% in 2025, then grew by 6 bps to 71.28% in 2026.
- Business Quant data shows CELG-RI's Gross Margin at 71.28% in Q2 2026, 70.22% in Q1 2026, and 67.23% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 68.19% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 74.74% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 73.54% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 78.02% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 83.60% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 72.04% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 79.76% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 72.78% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 73.05% |
| 10 | Bristol Myers Squibb | 188.27 Mn | -10.88 Bn | 9.25 Bn | 71.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71.28% |
| Mar 31, 2026 | 70.22% |
| Dec 31, 2025 | 67.23% |
| Sep 30, 2025 | 71.89% |
| Jun 30, 2025 | 72.52% |
| Mar 31, 2025 | 72.92% |
| Dec 31, 2024 | 61.01% |
| Sep 30, 2024 | 75.13% |
| Jun 30, 2024 | 73.22% |
| Mar 31, 2024 | 75.29% |
| Dec 31, 2023 | 76.08% |
| Sep 30, 2023 | 77.15% |
| Jun 30, 2023 | 74.38% |
| Mar 31, 2023 | 77.37% |
| Dec 31, 2022 | 77.27% |
| Sep 30, 2022 | 79.02% |
| Jun 30, 2022 | 77.12% |
| Mar 31, 2022 | 78.79% |
| Dec 31, 2021 | 80.34% |
| Sep 30, 2021 | 80.29% |